by telrheum | Jun 24, 2024 | Biologic Therapy, Anti-TNF, IL-23 Inhibitors, Il-6 inhibitors, JAK Inhibitor, Rituximab
Background: Rheumatoid arthritis (RA) patients often face higher cardiovascular risks due to chronic inflammation. Biologic disease-modifying antirheumatic drugs (biologic drugs) help control this inflammation, especially in those who don’t respond well to...
by telrheum | Jun 23, 2024 | Rheumatoid Arthritis, anti-CCP, Laboratory Testing
Background: The study aimed to determine if testing for anti-CCP3 antibodies in patients who are negative for anti-CCP2 antibodies but have musculoskeletal symptoms could better predict the progression to inflammatory arthritis (IA) or rheumatoid arthritis (RA)....
by telrheum | Jun 21, 2024 | Biologic Therapy, Anti-TNF, Spondyloarthritis
This study investigated why some children with juvenile spondyloarthritis (JSpA) do not respond to TNF inhibitors (TNFi), a common treatment. Researchers analyzed data from patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA)...
by telrheum | Jun 19, 2024 | Psoriatic Arthritis, Spondyloarthritis
Background/Purpose: The study explores the differences between males and females with axial juvenile spondyloarthritis (axJSpA), a type of juvenile inflammatory arthritis. The goal was to understand if there are distinct clinical and imaging features based on sex....
by telrheum | Jun 19, 2024 | Juvenile Idiopathic Arthritis, Rheumatic Drugs, tumour necrosis factor inhibitors (TNFis)
Background: Juvenile idiopathic arthritis (JIA) is a condition in children causing joint inflammation. Etanercept is a common medication for JIA, but the best dose for effectiveness is unclear. This study looks at whether increasing the dose of etanercept helps...